PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer
Status:
Terminated
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: PEG-interferon alfa-2b may interfere with the growth of tumor cells.
Colony-stimulating factors such as sargramostim may increase the number of immune cells found
in bone marrow or peripheral blood. Thalidomide may stop the growth of cancer by stopping
blood flow to the tumor. Combining PEG-interferon alfa-2b with sargramostim and thalidomide
may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving PEG-interferon alfa-2b together with
sargramostim and thalidomide works in treating patients with metastatic kidney cancer.